Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 61,882 shares, a decline of 42.5% from the November 30th total of 107,689 shares. Based on an average daily volume of 145,755 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.4% of the company’s shares are sold short. Currently, 0.4% of the company’s shares are sold short. Based on an average daily volume of 145,755 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

A number of brokerages have commented on PRE. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research note on Wednesday, October 8th. Wall Street Zen raised Prenetics Global from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th. Finally, Cantor Fitzgerald increased their price objective on shares of Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $32.00.

Institutional Trading of Prenetics Global

Several hedge funds have recently made changes to their positions in the stock. Nomura Holdings Inc. lifted its stake in Prenetics Global by 3.3% in the first quarter. Nomura Holdings Inc. now owns 333,528 shares of the company’s stock valued at $1,307,000 after buying an additional 10,576 shares during the last quarter. Aberdeen Group plc bought a new position in Prenetics Global in the 3rd quarter valued at about $979,000. UBS Group AG lifted its stake in shares of Prenetics Global by 581.9% in the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock worth $619,000 after acquiring an additional 39,733 shares during the period. Stevens Capital Partners acquired a new position in shares of Prenetics Global during the second quarter valued at approximately $137,000. Finally, JPMorgan Chase & Co. acquired a new stake in Prenetics Global in the third quarter worth approximately $65,000. Institutional investors own 25.01% of the company’s stock.

Prenetics Global Trading Down 0.2%

NASDAQ PRE traded down $0.03 on Friday, hitting $16.88. 49,047 shares of the stock traded hands, compared to its average volume of 139,638. The stock has a 50-day moving average of $14.53 and a 200 day moving average of $11.24. Prenetics Global has a twelve month low of $3.09 and a twelve month high of $18.48. The company has a market capitalization of $284.09 million, a P/E ratio of -8.32 and a beta of 0.35.

Prenetics Global (NASDAQ:PRE) last issued its earnings results on Monday, November 10th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.14. The company had revenue of $23.56 million during the quarter, compared to analyst estimates of $26.00 million. Prenetics Global had a negative return on equity of 30.12% and a negative net margin of 60.70%. As a group, equities research analysts expect that Prenetics Global will post -3.3 earnings per share for the current year.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.